Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Aesthet Surg J. 2010 May-Jun;30(3):451-6. doi: 10.1177/1090820X10374100.
The previous in vitro study showed that trehalose, when used as a cryoprotective agent (CPA) in an optimal concentration, can provide adequate protection of adipose aspirates during cryopreservation.
The authors evaluated the efficacy of trehalose in its optimal concentration for cryopreservation of human fat grafts in a well-established animal model.
In this study (n = 20 in each group), adipose aspirates were harvested and processed from a female patient; the protocol for freezing and thawing of fat grafts was the same as the in vitro study. In the control group, 0.5 mL of fresh fat grafts was injected into the posterior scalp of a nude mouse. In the cryopreservation group 1, a combination of dimethyl sulfoxide (in 0.5M) and trehalose (in 0.2M) was injected as a CPA. In the cryopreservation group 2, only the optimal concentration of trehalose (in 0.35M) was administered as a CPA. In both cryopreservation groups, 0.5 mL of cryopreserved fat grafts was thawed and injected into the animal in the same manner as the control group. All animals in each group were observed for gross appearance of maintained fat grafts over their posterior scalps for up to eight weeks. The final volume and weight of maintained fat grafts and their histology were evaluated at the end of the study.
Group 2, compared with group 1, respectively, had equivalently maintained volume (38.2 +/- 10.1% versus 46.1 +/- 14.4%, ns) and weight (34.1 +/- 12.1% versus 38.9 +/- 14.7%, ns). However, the results from both cryopreservation groups were still inferior to those from the control group (both P < .05). Histologically, the basic structure of adipose tissue was maintained in all three groups.
Trehalose, serving as a CPA in its optimal concentration, appears to provide adequate protection of human fat grafts during cryopreservation in vivo. Such protection is similar to that provided by the combination of dimethyl sulfoxide and trehalose as a CPA. Because of its safety and effectiveness, trehalose can possibly be administered to patients for long-term preservation of their fat grafts.
先前的体外研究表明，海藻糖作为一种最佳浓度的冷冻保护剂（CPA），在冷冻保存期间可以为脂肪抽吸物提供充分的保护。
作者在一种成熟的动物模型中评估了海藻糖在其最佳浓度下对人体脂肪移植物冷冻保存的效果。
在这项研究中（每组 20 例），从一名女性患者中采集和处理脂肪抽吸物；脂肪移植物的冷冻和解冻方案与体外研究相同。在对照组中，将 0.5ml 新鲜脂肪移植物注射到裸鼠的后头皮下。在冷冻保存组 1 中，将二甲基亚砜（0.5M）和海藻糖（0.2M）的混合物作为 CPA 注射。在冷冻保存组 2 中，仅以最佳浓度的海藻糖（0.35M）作为 CPA 给药。在这两组冷冻保存中，将 0.5ml 冷冻保存的脂肪移植物解冻，并以与对照组相同的方式注射到动物体内。每组的所有动物在后头皮上观察到维持的脂肪移植物的大体外观，最长达 8 周。研究结束时评估维持的脂肪移植物的最终体积和重量及其组织学。
与组 1 相比，组 2 分别具有同等维持的体积（38.2 +/- 10.1%对 46.1 +/- 14.4%，无统计学意义）和重量（34.1 +/- 12.1%对 38.9 +/- 14.7%，无统计学意义）。然而，来自这两组冷冻保存的结果仍不如对照组（均 P <.05）。组织学上，三组均保持了脂肪组织的基本结构。
海藻糖作为最佳浓度的 CPA，在体内冷冻保存期间似乎为人体脂肪移植物提供了充分的保护。这种保护类似于二甲基亚砜和海藻糖作为 CPA 的组合提供的保护。由于其安全性和有效性，海藻糖可用于患者以长期保存其脂肪移植物。
